COMMUNIQUÉS West-GlobeNewswire

RadNet to Make its Second Acquisition in Houston, Texas
10/04/2024
LOS ANGELES, April 10, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective outpatient diagnostic imaging services, today announces that it has signed a [...]
Medicines360 Appoints Erica Rogers to Board of Directors
10/04/2024
Rogers brings over 30 years of experience in the medical technology and healthcare sectors to Medicines360 SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Medicines360, a global mission-driven women's health company [...]
ViGeneron Announces First Patient Dosed in Phase 1b Clinical Trial of VG901 for the Intravitreal Treatment of Retinitis Pigmentosa
10/04/2024
VG901 is the first and only clinical-stage therapy designed to deliver a functional CNGA1 gene to retinal photoreceptor target cells in retinitis pigmentosa patients VG901, using ViGeneron’s proprietary next-generation [...]
EFA Technologies, pioneer in portable blood labs, enters Brazilian market after Anvisa approval of its portable RevDx device
10/04/2024
efa-technologies.com EFA also secures US $6.5 Million in funding, backed by existing investors and new partners Tel Aviv, Israel, 10 April 2024 - EFA Technologies, pioneers in portable blood labs, today announces the [...]
TILT Biotherapeutics Presents Clinical Data on TILT-123 in Combination with KEYTRUDA® (pembrolizumab) for Ovarian Cancer at AACR 2024
10/04/2024
Results Reveal Mechanism of Action and Correlative Analyses Data HELSINKI, Finland, April 10, 2024 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer [...]
Philips Respironics reaches agreement with US government on a consent decree creating a clear path forward
10/04/2024
April 10, 2024 Philips confirms that further to communicating the main terms of the Philips Respironics consent decree on January 29, 2024, Philips’ subsidiaries Philips Holding USA and Philips Respironics have now [...]
Recce Pharmaceuticals Selected by UK Government Innovation Agency to Participate in AMR Mission 2024
10/04/2024
Recce recognized by the United Kingdom Government Innovation Agency among the most promising organizations for the UK AMR Inward Mission 2024 Recce chosen as one of 18 organizations globally for its potential to tackle [...]
Mobile-health Network Solutions Announces Pricing of $9 Million Initial Public Offering
10/04/2024
Singapore, April 09, 2024 (GLOBE NEWSWIRE) -- Mobile-health Network Solutions (“ MNDR ” or the “ Company ”), a leading telehealth solutions provider in Singapore, today announced the pricing of its firm commitment [...]
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)
09/04/2024
– Twenty patients with indolent (n=18) and aggressive (n=2) R/R B-NHL received evorpacept plus standard rituximab and lenalidomide (“R 2 ”) – Evorpacept plus R 2 was well tolerated with a safety profile similar to [...]
Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024
09/04/2024
Poster outlines the parameters for developing a flow-cytometry-based PPMP as a companion diagnostic to predict volasertib responders, based on a proof-of-concept study using 41 primary acute myeloid leukemia (AML) [...]
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
09/04/2024
Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses Potentially best-in-class CDK9 inhibitor, PRT2527, [...]
Auron Unveils Preclinical Data Supporting its Lead Program and Ability of its AURIGIN™ Platform to Generate Targeted Cancer Therapies at AACR Annual Meeting
09/04/2024
Preclinical data from lead program addressing AURIGIN-identified KAT2A/B target showed significant cell state shift and tumor growth inhibition across multiple primary cancer models AURIGIN overview highlighted [...]
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
09/04/2024
First-in class BRM (SMARCA2) selective inhibitor FHD-909 demonstrated favorable tolerability and dose-dependent single agent activity in BRG1 mutated cancers preclinically; IND filing on track for Q2 2024 Robust [...]
Silk Road Medical to Report First Quarter 2024 Financial Results on April 30, 2024
09/04/2024
SUNNYVALE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results [...]
Dentsply Sirona to Host First Quarter Conference Call on May 2nd
09/04/2024
CHARLOTTE, N.C., April 09, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will be hosting an investor conference call and live webcast [...]
IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024
09/04/2024
- Preclinical data supports potential for proprietary nsCAR platform to selectively eliminate cancer cells while preserving healthy tissue - Gamma-delta nsCAR platform emerging as an advanced technology for targeting [...]
Frontier Medicines Presents New Data for First-In-Class Dual ON+OFF KRAS G12C Inhibitor FMC-376 at the AACR Annual Meeting
09/04/2024
- Pre- clinical results demonstrate the combination of FMC-376 with PD-1 immunotherapy increases survival and response rates compared to PD-1 alone - FMC-376 is broadly active in KRASG12C mutant containing PDX models [...]
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
09/04/2024
100% reduction of target lesions in one melanoma and one pancreatic cancer patient observed among 4 Partial Responses (PR) to date which include 2 of 4 evaluable dose expansion patients and 2 of 2 MSI-H patients Durable [...]
Certara to Report First Quarter 2024 Financial Results on May 7th, 2024 and Participate in the BofA Securities Healthcare Conference
09/04/2024
PRINCETON, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2024 after the market [...]

Pages